In a report released today, Kalpit Patel from B. Riley Securities reiterated a Buy rating on Verastem, with a price target of $16.00. The company’s shares closed yesterday at $9.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Patel is ranked #1322 out of 10036 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verastem with a $15.60 average price target.
VSTM market cap is currently $550.2M and has a P/E ratio of -2.63.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VSTM in relation to earlier this year. Last month, Daniel Calkins, the CFO of VSTM sold 82.00 shares for a total of $748.31.
Read More on VSTM:
Disclaimer & DisclosureReport an Issue
- Verastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic Outlook
- Leerink says competitor data suggest promising view for Revolution’s zoldonrasib
- Verastem Updates on Cancer Therapy Developments
- Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?
- Verastem price target lowered to $14 from $16 at Mizuho
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)